SHAREHOLDER INFORMATION

Our Long-Middle-Short term strategy plan has been approved to kickoff IPO process in the middle of year 2019 and hopefully to be officially in the Taiwan market in 2020. In order to fast expand our clinical trials and immunotherapy to more region and more cancers we plan fund raising in 2019 and 2020. We warmly welcome venture or company or individual investment.